INSTANYL

Active ingredient:

fentanyl citrate, Quantity: 0.785 mg/mL (Equivalent: fentanyl, Qty 0.5 mg/mL)

Available from:

Takeda Pharmaceuticals Australia Pty Ltd

INN (International Name):

Fentanyl citrate

Pharmaceutical form:

Spray, nasal

Composition:

Excipient Ingredients: monobasic sodium phosphate dihydrate; dibasic sodium phosphate dihydrate; purified water

Administration route:

Nasal

Units in package:

2 bottles per carton, 8 bottles per carton, 6 bottles per carton, 10 bottles per carton

Prescription type:

(S8) Controlled Drug

Therapeutic indications:

Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain.

Product summary:

Visual Identification: Nasal spray; Container Type: Bottle, with integral pump - manual actuated; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2013-06-17